PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics. The two companies will work together to ensure the production of Viking’s GLP ...

Dr. Mensen adds that tirzepatide (Mounjaro or Zepbound), a dual GLP-1/GIP agonist, may also be recommended. "Based on the fact that each individual experience with this medication is different ...

CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735. CordenPharma provides fill-finish for the drug candidate's subcutaneous ...

However, Zepbound is proven to be more effective for weight loss than Wegovy since it targets two hormones, GLP-1 and GIP. Total Zepbound sales were $4.93 billion in 2024 for Lilly. Zepbound had a ...